精准诊断与治疗，助力高危基因突变乳腺癌患者降低复发风险

Core Viewpoint - Breast cancer is a significant health threat to women in China, but advancements in medical treatment have improved the 5-year survival rate to 83.2% [1] Group 1: Current Situation and Statistics - Approximately 72% of breast cancer patients in China are diagnosed at an early stage, yet 30% of high-risk patients may experience recurrence within the first few years [1] - The 5-year survival rate for late-stage breast cancer is only 20%, with a median survival time of 2-3 years [1] Group 2: Genetic Factors and Risk Assessment - 5%-10% of breast cancer patients have hereditary breast cancer due to genetic mutations, with BRCA1/2 being the most critical susceptibility genes [2] - 5%-20% of breast cancer patients in China carry BRCA mutations, which are more common in HER2-negative breast cancer, particularly in triple-negative breast cancer (TNBC) [2] Group 3: Importance of Genetic Testing - Genetic testing for BRCA1/2 is recommended for patients with a family history of breast cancer and those diagnosed with invasive TNBC, especially with lymph node involvement [3] - Accurate diagnosis through genetic testing is essential for developing personalized treatment plans and improving treatment efficacy [3] Group 4: Treatment and Prevention Strategies - New treatment options based on genetic mutations require clear identification of the mutation-carrying population for effective outcomes [4] - Regular breast cancer screenings are advised for women aged 35 to 70, along with self-examinations to facilitate early detection and treatment [4]